|
Celgene's Customers Performance
CELG
|
CELG's Source of Revenues |
In the Q3, Celgene Corp's corporate clients experienced a reduction by -2.59 % in their costs of revenue, compared to a year ago, sequentially costs of revenue were trimmed by -24.86 %. During the corresponding time, Celgene Corp recorded revenue increase by 16.14 % year on year, sequentially revenue grew by 2.73 %. While revenue at the Celgene Corp's corporate clients recorded rose by 23.84 % year on year, sequentially revenue fell by -1.42 %.
• List of CELG Customers
|
|
Customers of Celgene Corp saw their costs of revenue decrease by -2.59 % in Q3 compare to a year ago, sequentially costs of revenue were trimmed by -24.86 %, for the same period Celgene Corp recorded revenue increase by 16.14 % year on year, sequentially revenue grew by 2.73 %.
• List of CELG Customers
Select the Relationship:
|
|
Select the Category:
|
|
Customers Net Income grew in Q3 by |
Customers Net margin grew to |
29.46 % |
3.96 % |
Celgene's Comment on Sales, Marketing and Customers
We promote our brands globally through our commercial organization which supports
our currently marketed brands and prepares for the launches of new products,
as well as new indications for existing products. We have a team of dedicated
market access professionals to help physicians, patients and payers understand
the value our products deliver. Given our goal to ensure that patients who might
benefit from our therapies have the opportunity to do so and given the complex
reimbursement environment in the United States, we offer the services of Celgene
Patient Support® or similar outside services to serve as a dedicated, central
point of contact for patients and healthcare professionals who use or prescribe
Celgene products. Celgene Patient Support® is a free service that helps
patients and healthcare professionals navigate the challenges of reimbursement,
providing information about co-pay assistance and answering questions about
obtaining Celgene products.
In most countries, we promote our products through our own sales organizations.
In some countries, particularly in Latin America, we partner with third-party
distributors. Generally, we distribute our products through commonly used channels
in local markets. However, REVLIMID®, POMALYST®/IMNOVID® and THALOMID®/Thalidomide
CelgeneTM are distributed under mandatory risk-management distribution programs
tailored to meet local authorities' specifications to provide for their safe
and appropriate distribution and use.
| |